Sanofi's Genzyme Pulls 19 Lots Of Thymoglobulin Vials

Law360, Washington (August 28, 2012, 3:10 PM EDT) -- Sanofi SA subsidiary Genzyme Corp. issued a voluntary recall of 19 lots of its kidney transplant rejection drug Thymoglobulin after discovering some lots of the drug may have stability issues, the company and U.S. Food and Drug Administration announced Monday.

Genzyme said that one Thymoglobulin lot produced negative results during stability testing, prompting a recall of the 25-milligram vials that will affect 52 countries. The affected lots were manufactured using the same raw materials or those of comparable quality, which the company believes is the cause...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.